Tuesday, May 22, 2012

Site Search

Archive for the ‘R & D’ Category

EC Conditionally Approves Cell Therapeutics’ Pixantrone for Non-Hodgkin Lymphoma

The EC granted Cell Therapeutics’ Pixuvri® (pixantrone) conditional marketing authorization for use as monotherapy in the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The firm says it will make the drug available in the EU immediately, initially through a named patient basis.

Conditional approval of Pixuvri was granted on the basis of Cell Therapeutics’ Phase III PIX 301 study, which showed that 20% of patients treated using the drug achieved a complete response or unconfirmed complete response, compared with 6% of patients treated using a comparator chemotherapy. In addition, average progression-free survival was 2.6 months longer among Pixuvri-treated patients, at 10.2 months.

Under terms of the conditional marketing approval, Cell Therapeutics will complete a post-marketing study to confirm the clinical benefits of Pixuvri. The EMA’s Committee for Medicinal Products for Human Use will also accept for review data from an ongoing Phase III trial, PIX306, which is comparing Pixuvri-rituximab to gemcitabine-rituximab in relapsed patients with aggressive B-cell NHL who aren’t eligible for autologous stem cell transplantation. The firm will make the trial results available to the European Medicines Agency by mid-2015.

Pixantrone is an aza-anthracenedione formulated for delivery via a peripheral intravenous catheter. Cell Therapeutics claims the drug demonstrates structural and physicochemical properties that mean it doesn’t to bind iron and propagate oxygen radical production or form long-lived hydroxyl metabolites, which are the mechanisms believed to be responsible for induced acute and chronic cardiotoxicity associated with other anthracycline drugs. These benefits mean pixantrone can be administered to patients over the long term, without unacceptable cardiotoxicity risks.

In January Cell Therapeutics voluntarily withdrew its NDA for Pixuvri in the U.S., due, it says, to a lack of time to prepare for FDA’s Oncologic Drugs Advisory Committee review of the drug in advance of the Prescription Drug User Fee Act (PDUFA) date, which had been set for April 24. The firm plans to re-submit the NDA later in 2012.

Source: http://www.genengnews.com/

TAP, Open University to Develop 3-D CNS Tissue Models for Research, Drug Testing

TAP Biosystems and the U.K.’s Open University (OU) established a partnership to develop 3-D human central nervous system (CNS) tissue models based on TAP’s collagen RAFT technology for drug discovery and preclinical drug testing. The aim is to manufacture gel-based neural tissue models using glial cells and neurons that can be used for research and for applications including preclinical screening of drug candidates.

TAP’s RAFT (real architecture for 3-D tissue) platform has been designed to enable the creation of complex 3-D cell cultures from collagen, in a simple-to-use 96-well plate format. TAP claims that the system requires less than an hour to generate up to 96 cell cultures simultaneously.

The aim is to generate CNS tissue equivalents that closely mimic the cells’ in vivo environment. “2-D cell cultures of astrocytes and neurons don’t behave in the same way as they do in a living organisms, and this can limit their range of uses,” explains James Phillips, Ph.D., at the Open University’s Faculty of Science. “We are using the RAFT process with astrocyte-seeded collagen gels. The cellular alignment created then allows the other types of cells in our 3-D tissue model to organize themselves as they would in a natural environment.”

This 3-D level of organization will make it possible to simulate and monitor the interaction between glial cells and regenerating neurons, for example after CNS injury, the partners claim. The ability to control variables in the tissue model environment will also facilitate the study of glial and neuronal cell response to drug candidates.

“Such models could contribute to generating more accurate data from novel therapies and may even result in a reduction of the numbers of animal studies necessary for screening potential neuroprotective therapies,” suggests Rosemary Drake, Ph.D., TAP’s CSO.

The firm’s collaboration with OU comes less than a month after TAP announced receipt of additional funding from the U.K.’s Technology Strategy Board to support development of a RAFT-based biomimetic cornea into initial human trials. The project is being undertaken in partnership with scientists the Institute of Ophthalmology at University College London.

Source: http://www.genengnews.com/

HSC Transplants Give Glioblastoma Patients Longer Life, Tolerance to Alkylating Agent Chemotherapy

Scientists report positive data from a first-in-man study evaluating the bone marrow-protective effects of genetically modified autologous hematopoietic stem cell transplants in glioblastoma patients treated using chemotherapy and benzylguanine. The results, published in Science Translational Medicine, showed that of the three patients given the transplants prior to combination therapy, two survived much longer than average, and the third remains alive with no disease progression almost three years later.

The study, led by researchers at the Fred Hutchinson Cancer Research Center’s Clinical Research Division, demonstrates that the engineered stem cells have a chemoprotective effect, maximizing the drug dose that can be administered. The results are described in a paper titled “Extended Survival of Glioblastoma Patients After Chemoprotective HSC Gene Therapy.”

A major barrier to the successful use of cancer chemotherapy is organ toxicity, and primarily bone marrow toxicity (hematopoietic toxicity), which causes blood cell counts to drop and increases susceptibility to infection. Bone marrow toxicity resulting form alkylating agents has been linked with low or absent expression of the methylguanine methyltransferase (MGMT) gene, the researchers explain. However, some tumors, including aggressive brain tumors, paradoxically over-express MGMT, which results in the tumor cells being chemotherapy-resistant but the bone marrow cells being particularly sensitive to alkylating agents. Prognosis is thus particularly poor in patients with glioblastomas that express an unmethylated promoter for the MGMT gene because the increased increased MGMT activity in tumor cells reduces the cytotoxicity of alkylating chemotherapies such as temozolomide (TMZ) by repairing the drug-induced DNA damage.

It’s feasible that overcoming MGMT-related tumor-cell resistance to chemotherapy can be achieved by administering an MGMT inhibitor, O6-benzylguanine (O6BG), in combination with alkylating agent chemotherapy. However, Phase I and II studies have shown that this approach leads to significant hematopoietic toxicity, the researchers continue. In order to try and overcome this, the Fred Hutchinson team carried out a small clinical trial to test a gene therapy approach in which patients received transplants of their own hematopoietic stem cells (HSCs) that had been engineered to carry a mutant MGMT gene (P140K).

The mutant gene engineered into the HSCs displays the same activity as wild-type MGMT, but also confers both the stem cells and their progeny with resistance to O6BG. Prior in vitro and in vivo preclinical work has demonstrated that O6BG-resistant MGMT P140K gene expression can protect the hematopoietic system from toxicity associated with combined O6BG and alkylator chemotherapy.

The reported clinical study involved giving three glioblastoma patients autologous transplants of P140K-modified hematopoietic stem and progenitor cells after nonmyeloablative conditioning with the FDA-approved chemotherapeutic agent BCNU. This step was carried out because data from previous studies indicate that BCNU could facilitate engraftment of transplanted gene-modified cells while maintaining stable disease during transplant recovery.

After BCNU treatment and successful engraftment of modified stem cells, the patients were treated using between three and nine cycles of chemotherapy comprising O6BG and TMZ. Procedural details are reported in the published paper, but the authors stress that all patients demonstrated recovery from BCNU, engraftment of P140K gene-modified cells, and maintenance of stable disease during the transplant period. This, they say, supports “the clinical feasibility of this approach”. Moreover, the dose of BCNU administered prior to HSC transplantation was much lower than doses of the drug used for chemotherapy for glioblastoma, and resulted in only mild myelosuppression with no apparent toxicity.

PCR analyses confirmed that all three stem cell recipients exhibited gene-modified cells among peripheral blood granulocytes and lymphocytes up to 14 months after transplantation. Hematopoietic recovery was observed in each patient after each chemotherapy cycle, and the P140K gene-modified cells were found in multiple hematopoietic lineages after several rounds of combination treatment with O6BG and TMZ.

Importantly, chemotherapy was well tolerated, and all patients demonstrated acceptable hematopoietic toxicity and no significant extramedullary toxicity. “All three patients treated surpassed the median survival for glioblastoma patients with unmethylated MGMT promoter status in tumor cells (12 months), with two of three patients displaying stable disease at 12 months from diagnosis and one patient displaying no evidence for disease progression,” the authors state.

“These data support continued development of P140K-modified hematopoietic progenitor and stem cells as a chemoprotective strategy in cancers, including glioblastoma, where benefit from combined O6BG/DNA alkylating agent chemotherapy has been hindered by hematopoietic toxicity. Lack of extramedullary toxicity in the study patients suggests that this approach will allow for administration of multiple cycles of this chemotherapy, possibly at higher, more effective, doses, potentially leading to better treatment outcomes.”

Source: http://www.genengnews.com/

Aeres, IDRI to Take Preventive and Therapeutic TB Vaccine into Phase I

Nonprofit organizations Aeres and the Infectious Disease Research Institute (IDRI) are teaming up to develop the latter’s tuberculosis vaccine candidate, which is projected to start in clinical trials this year. The vaccine, ID93/GLA-SE, targets both active tuberculosis and latent disease, IDRI claims. The organization anticipates the vaccine could be used both for prophylactic with or without BCG vaccination, or therapeutically in combination with anti-tuberculosis drugs to combat active infection.

ID93/GLA-SE is a recombinant fusion polyprotein comprising key virulence- and latency-associated Mycobacterium tuberculosis antigens linked to IDRI’s Glucopyranosyl Lipid A stable emulsion (GLA-SE) adjuvant. GLA-SE is a Toll-like receptor 4 (TLR4) agonist formulated in an oil-in-water emulsion, which is essentially a synthetic analog of GlaxoSmithKline Biologicals’ Monophosphoryl Lipid A adjuvant, the organizations state. GLA-SE has been evaluated in humans, but not for a tuberculosis vaccine. The M. tuberculosis antigens incorporated in the vaccine include Rv2608, Rv3619, Rv3620, and Rv1813. Preclinical studies with ID93/GLA-SE have been carried out with funding from the National Institute of Allergy and Infectious Diseases, and demonstrated that the vaccine provided significant protection against M. tuberculosis either with or without previous priming with BCG.

Aeres is dedicated to the development of vaccines and biologics against TB, and has developed or is supporting the development of six TB vaccine candidates. Five of these are undergoing Phase I or II studies. IDRI is focused on the development of products to prevent, diagnose, and treat infectious diseases of poverty. The organization’s TB program is centered on the development of prophylactic and therapeutic vaccines, rapid diagnostics, and antibiotics against drug-resistant strains.

Source: http://www.genengnews.com/

454, SoftGenetics Enter Co-Promotion Deal in Next-Gen Sequencing Informatics

454 Life Sciences and SoftGenetics inked an agreement centered on informatics solutions for sequencing. Under the co-promotion arrangement, users of 454 sequencing systems will have access to data-analysis options provided by SoftGenetics’ NextGENe® software.

NextGENe is a free-standing solution that is compatible with 454 next-generation sequencing (NGS) data. The companies say that it can be leveraged across a variety of applications including targeted amplicon resequencing, exome sequencing, transcriptome sequencing, forensic profiling, and more. The software package also reportedly provides an extensive GS Data Analysis Software suite.

“This agreement permits both 454 and SoftGenetics the opportunity to more fully understand and address the rapidly changing needs of the NGS marketplace,” states SoftGenetics co-founder John Fosnacht. “SoftGenetics welcomes the opportunity to work closely with our colleagues at 454 Life Sciences to provide our mutual customers with integrated sequencing and analysis systems that not only deliver the required quality and sensitivity but also the efficiency needed in today’s scientific and economic environments.”

SoftGenetics offers 30-day trials and no-cost, web-based training on its genetic analysis software packages. The company has similar NextGENe arrangements with Life Technologies and Ambry Genetics. Last April SoftGenetics entered into a reseller’s agreement with Life Tech, which will offer the NextGENe software to process sequencing data from the Ion Personal Genome Machine. In December 2009, Ambry partnered with SoftGenetics so that it could also use the NextGENe solution in its NGS projects.

Source: http://www.genengnews.com/

ArcDia Raises €2.7M for Multianalyte Respiratory Infection POC Platform

ArcDia raised €2.7 million (about $3.5 million) in an investment round to expand its mariPOC® diagnostic system. The point-of-care platform simultaneously tests for nine common viruses and bacteria responsible for respiratory tract infections using a single nasopharyngeal or throat swab, or sample of aspirate. Pathogens detected include influenza A/B, respiratory syncitial virus, and parainfluenza viruses 1, 2, and 3, and results are generated in 20 minutes.

Based on Finnish firm ArcDia’s TPX detection technology, the IVD-CE marked mariPOC was launched on the European market in late 2010, and is used by major hospitals for routine clinical diagnostics. “No other diagnostics test platform has been able to provide this functionality and cost-effectiveness to enable respiratory tract infections testing at point-of-care,” comments Aleksi Soini, ArcDia’s CEO.

ArcDia’s TPX system uses two-photon excitation of fluorescence detection, which allows separation-free analysis from just microvolumes, the firm explains. Polystyrene microparticles are used for the solid phase reaction carriers for the formation of fluorescence-based immunocomplexes generated as a result of antigen-antibody binding. Detection of the immunoassay fluorescence signal is then carried out by means of two-photon excitation from the surface of individual microspheres.

Source: http://www.genengnews.com/

Eleven Increases Series A Fundraising to $45M for Protein Therapeutics Pipeline

Eleven Biotherapeutics secured $20 million from new and existing investors in an extension to its Series A financing, which takes the total raised to $45 million. JAFCO joined the fundraising round as new investor together with financial input from existing investors Third Rock Ventures and Flagship Ventures.

Eleven Bio will use the funds to progress its initial protein therapeutic candidate EBI-005 into clinical development as a topical treatment for surface of the eye diseases as well as progress its earlier-stage pipeline. Initial clinical development of the interleukin-1 receptor antagonist is expected to start during 2012 for the treatment of dry eye syndrome. The firm cialms EBI-005 is the first rationally designed IL-1 receptor inhibitor for topical administration to be optimized for the treatment of drye eye disease and other ocular surface inflammatory disorders.

“This financing provides us with a strong financial foundation and firmly validates our investors’ enthusiasm for Eleven’s ability to develop novel, best-in-class protein therapeutics,” comments CEO Abbie Celniker, Ph.D.

Eleven is exploiting its AMP-Rx platform for the rational design of what it calls ‘fit for purpose’ therapeutic proteins that display the optimum physical, efficacy, and selectivity characteristics. Besides EBI-005, the firm’s preclinical pipeline includes an anti-IL-6 candidate against autoimmune and inflammatory disease, an IL-17 receptor antagonist for the potential treatment of ocular inflammation and uveitis, and an anti-myostatin antibody for treating muscle wasting. Early-stage research programs are in progress in the fields of hematology, immunosuppression, metabolism, inflammation, and gout therapy.

Source: http://www.genengnews.com/

Kineta, Universities of Washington and Texas Win $8.1M for Antiviral Biodefense Drugs

A collaboration between Kineta, the University of Washington, and the University of Texas Medical Branch has been awarded $8.1 million in funding by the National Institute of Allergy and Infectious Diseases (NIAID) to develop antiviral drugs against potential biothreat agents as Ebola, plague, and Japanese encephalitis.

Researchers at the University of Washington’s NIH-sponsored Center for the Study of Immune Mechanisms of Virus Control have been working to understanding the basis of the body’s innate immunity to virus infection and the intracellular processes and virus-host interactions that control viral replication. The program will build on existing collaborations between Kineta and the University of Washington, including ongoing NIAID-funded research to develop antiviral drugs and vaccine adjuvants.

As part of the latest NIAID partnership, Kineta will lead drug optimization and in vivo pharmacology work, and scientists at the University of Washington will provide additional bioinformatics and systems biology genomics analysis. Collaborators at the University of Texas Medical Branch’s Galveston National Laboratory will oversee research on biosafety level 4 viral agents, including Ebola and Nipah viruses.

“This award enables us to push further and work with more high-priority viruses,” comments University of Washington professor Michael Gale Jr., Ph.D., principal grant investigator. “These diseases are major concerns of the U.S. government for their risk of sparking a pandemic and their potential use as bioterrorist weapons. By utilizing an innate immune pathway we hope to develop better drugs that won’t be outsmarted by viral mutation.”

Established in 2007, Kineta is developing drugs that act at the level of the innate and adaptive immune systems to treat infectious diseases and autoimmune disorders. Its primary target is retinoic acid inducible gene I protein (RIG-1), a key element of the innate immune system. Kineta says it has identified compounds that can influence RIG-1 and trigger natural anti-infection immune responses. The aim is to develop broad-based antiviral products against a range of infectious diseases such as HIV, hepatitis C, influenza, and West Nile Virus, and also exploit the RIG-1 platform to generate vaccine adjuvants.

Source: http://www.genengnews.com/

Transcriptional Diversity Found in Circulating Tumor Cells from Individual Breast Cancer Patients

Scientists have shown that there is considerable transcriptional diversity between individual circulating tumor cells (CTCs) found in the blood of a single cancer patient, indicating that multiple treatments may be required to adequately kill off a patient’s cancer. Researchers led by a team at Stanford University used an immunomagnetic enrichment device technique known as MagSweeper to isolate CTCs from blood samples taken from breast cancer patients. The investigators then used microfluidic-based single-cell transcriptional profiling to look at the expression of 87 cancer-associated and reference genes in individual CTCs.

The results, reported in PLoS One, showed that there was significant heterogeneity in the transcription profiles of CTCs released into the blood, even among those from a single patient. Importantly, the expression profiles of all CTCs were very different from those of seven different primary and metastatic human breast cancer cell lines that are widely used for drug discovery and in vitro drug testing. “Our finding suggests that perhaps they’re not that helpful as models of spreading cancers,” claims lead investigator Stefanie S. Jeffrey, M.D., professor of surgery and chief of surgical oncology research at Stanford’s Department of Surgery.

The researchers describe their findings in a paper titled “Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.”

The treatment of metastatic cancer is determined largely by biomarkers from the primary tumor, despite the fact that metastatic tumors and primary tumors may be very different. Given that metastases are seeded at distal sites by CTCs released into the bloodstream, a method for accurately profiling such cells could provide valuable information for guiding therapy, the authors note. However, accurate characterization of CTCs is hampered both due to contamination with white blood cells and the limited sensitivity of analytical methods, which means analyses may have to carried out on pooled CTCs.

To demonstrate that single-cell transcription profiling is possible for CTCs, the team used the MagSweeper enrichment technology to isolate CTCs from breast cancer patient blood samples, and then applied microfluidic-based single-cell transcriptional profiling technique to determine the expression levels of 87 genes in individual CTCs. Blood samples were taken from 20 breast cancer patients with primary tumors, and 30 patients with metastatic disease. Of the 87 genes evaluated, 31 were consistently detected in at least 15% of the CTCs analyzed. Apart from three reference genes that were expressed in all the CTCs, the 28 remaining genes most commonly expressed were found to be relevant to nine basic functional categories: epithelial phenotype, epithelial mesenchymal transition, metastasis, PI3K/AKT/mTOR pathway, apoptosis, cell proliferation, DNA repair, cell metabolism, and stem cell phenotype.

Clustering analyses indicated that while the transcription profiles of CTCs varied considerably, they fell into two broad groups, both of which could be present in the same patient. Cluster I represented a relatively small proportion of the CTCs which, in comparison with cluster II, were characterized by stronger expression of S100A9, CD24, VIM, CXCR4, MAPK14, AKT2, PIK3R1, CTNNB1, CD44, and ZEB2. Importantly, both clusters robustly expressed a number of metastasis-associated genes.

Of particular note was the finding that the CTCs were almost exclusively triple negative (i.e., lacking Er, PR, and Her2 expression), irrespective of whether the patient’s primary tumor was triple negative or not. “Loss of expression of Er/PR/Her2 in CTCs noted in our particular patient sample could explain why therapies that target these biomarkers may fail to control end-stage disease,” professor Jeffrey et al point out.

And surprisingly, all the CTC transcription profiles differed greatly from those of three commonly used primary and four metastatic human breast cancer cell lines. “Overall, expression patterns of <10% (2/28) common tumor-associated gene profiles of CTCs were recapitulated by a subset of tumor cell line models,” the investigators write.

“Although CTC heterogeneity between patients is well recognized, an important finding in our study was that individual CTCs did not cluster by patient or disease stage (primary cancer vs. metastatic cancer), which again supports the concept that these cells belong to subpopulations with phenotypes fundamentally different from pooled tumor tissue,” they conclude. Studying and phenotyping the primary tumor alone may lead to suboptimal treatment selection … Our finding of CTC variability is consistent with primary and metastatic tumor heterogeneity and suggests that single cell phenotyping of CTCs is a practical approach to exploit this variability for the effective implementation of molecular guided cancer therapy on a more comprehensive scale than possible with mutational analysis of a few known genes.”

Source: http://www.genengnews.com/

Islet Licenses Yale IP to Identify Beta Cell Death Before Diabetes Manifests

Islet Sciences negotiated an exclusive license to a diagnostic technology developed at Yale University that it says can identify beta cell death and help diagnose diabetes well before clinical symptoms present. The IP is based on the detection of circulating hypomethylated B cell-derived DNA, as a biomarker of B cell destruction.

Islet Sciences is focused on the development of transplantation therapies for diabetes based on its porcine islet cell and polymer microencapsulation technologies. The firm’s initial product, Islet Sciences-P™, is being developed as a ready-to-use vialed suspension of microencapsulated porcine islet cells for injection into the abdominal cavity.

In April Islet acquired DiaKine Therapeutics, which is developing a pipeline of treatments for diabetes. DiaKine’s most advanced product, Lisofylline, is in Phase II development as an intravenously administered adjunct therapy to islet cell transplantation. The drug is designed to improve the function of insulin-producing islet cells and protect them from damage and premature death associated with type 1 diabetes. A subcutaneous formulation of Lisofylline is in addition being evaluated in a Phase I study in newly diagnosed type 1 diabetes patients.

DiaKine’s preclinical pipeline includes a range of orally bioavailable immune modulators, including candidates for the treatment of latent autoimmune diabetes in adults and insulin-dependent type 2 diabetes, and diabetic nephropathy and retinopathy. Last month DiaKine received two separate grants from the NIH ($1.83 million) and Iacocca Foundation ($250,000).

Source: http://www.genengnews.com/

Santen Nabs Japanese Co-Promotion Rights to Bayer and Regeneron’s Eylea

Santen Pharmaceuticals negotiated co-promotion rights to Regeneron Pharmaceuticals and Bayer HealthCare’s Eylea® (aflibercept; VEGF Trap-Eye) injection in Japan. Bayer’s Japanese subsidiary Bayer Yakuhin has already submitted a marketing application to the country’s regulatory authority for use of Eylea in the treatment of neovascular age-related macular degeneration (wet AMD). The deal with Santen means Bayer and Regeneron have in addition changed their previous 50/50 profit-share agreement for Eylea in Japan to a royalty-based deal.

Eylea was approved in the U.S. for the treatment of wet AMD in November 2011. Marketing authorization has also been granted in Australia, and applications in Europe and other markets have been submitted by Bayer. A Phase III wet AMD trial is ongoing in China. Phase III trials are also in progress to evaluate Eylea for the treatment of diabetic macular edema, myopic choroidal neovascularization, and branch retinal vein occlusion. Regeneron has filed an sBLA in the U.S. for Eylea in the treatment of central retinal vein occlusion.

Bayer and Regneron are collaborating on the global development of Eylea. Under terms of the deal, Regeneron retains all rights to the drug in the U.S., and Bayer HealthCare has marketing rights outside the U.S., where the companies will share profits from sales of Eylea equally (excluding Japan).

Eylea is a recombinant fusion protein comprising portions of human VEGF receptors 1 and 2 and extracellular domains fused to the Fc portion of IgG1. The product is formulated for intravitreal administration.

Source: http://www.genengnews.com/

Celgene Pays Epizyme $90M for Ex-U.S. Rights to Histone Methyltransferase Inhibitor

Celgene is paying Epizyme $90 million up front to established a partnership focused on the discovery, development, and commercialization of histone methyltransferase (HMT)-inhibiting drugs for genetically defined cancers. The up-front fee includes an equity investment in Epizyme and gives Celgene exclusive immediate ex-U.S. rights to its partner’s existing DOT1L HMT inhibitor program against mixed lineage leukemia (MLL).

Under terms of the deal Celgene also retains an exclusive option to license ex-U.S. rights to other Epizyme HMT inhibitor programs over an initial three-year period. Epizyme retains all U.S. rights to resulting products, and could earn up to another $160 million in milestones for each HMT inhibitor licensed by Celgene, and potentially double-digit royalties on ex-U.S. sales. The firms will work jointly to discover and develop HMT inhibitors, and will co-fund global development of collaborative programs.

Celgene’s expertise in epigenetic cancer therapies and Epizyme’s histone myethyltransferase platform are highly complementary, the partners claim. “Through this collaboration, Epizyme gains access to Celgene’s leading drug development resources, enabling us to substantially increase the breadth and depth of our efforts while retaining U.S. rights to our pipeline of personalized therapies,” comments Robert Gould, Ph.D., Epizyme CEO.

Epizyme is focused on the discovery and development of small molecule HMT inhibitors. The firm’s initial therapeutic target is MLL, a form of acute leukemia characterized by the presence of a chromosomal alteration (MLL-translocation) that recruits DOT1L activity to aberrant gene locations, leading to increased expression of specific gene products that drive leukemia cell proliferation. The small molecule DOT1L inhibitor is designed to selectively kill MLL cells, while sparing cells that don’t carry the MLL-translocation.

DOT1L is being developed in collaboration with the Leukemia and Lymphoma Society. Last month Eipzyme reported achieving a preclinical milestone in the program, and said it has to date received $2.6 million of potentially $7.5 million in funding under the partnership to support the DOT1L program through Phase I development.

The firm’s second lead program, EZH2, is in development in partnership with Eisai for the treatment of certain nonHodgkin lymphomas and breast cancer subtypes. The compound is designed to target the catalytic center of a multiprotein complex known as polycomb repressive complex 2 (PRC2). Epizyme and Eisai inked their deal for the EZH2 program back in March 2011.

Source: http://www.genengnews.com/gen-news-highlights/celgene-pays-epizyme-90m-for-ex-u-s-rights-to-histone-methyltransferase-inhibitor/81246684/

http://www.genengnews.com/gen-news-highlights/researchers-find-gene-key-to-maintaining-lung-cancer-stem-cells-promoting-tumor-initiation-and/81246678/

Scientists have identified a single gene that appears to be central to the maintenance of non-small cell lung cancer (NSCLC) cancer stem cells, as well as the initiation of tumor formation, growth and metastasis in vivo. A Mayo Clinic College of Medicine team found that cancer stem cells (CSCs) in oncosphere cultures demonstrated high expression levels of matrix metalloproteinase-10 (Mmp-10; or stromelysin 2), and that knocking down Mmp10 expression in these cells resulted in the loss of stem cell markers and the inhibition of oncosphere growth, clonal expansion, and tumor development. Mmp10-deficient oncospheres were in addition far less able to initiate tumor development than unmodified oncospheres when injected into experimental mice.

Reporting their findings in PLoS One, Alan P. Fields, M.D., and colleagues say subsequent analysis of gene expression data from human cancers highlighted a strong correlation between tumor Mmp10 expression and metastasis in a range of tumor types. “Our data demonstrate for the first time that Mmp10 is a critical lung cancer stem cell gene and novel therapeutic target for lung cancer stem cells,” they conclude. The investigators’ results are published in a paper titled “Matrix Metalloproteinase-10 Is Required for Lung Cancer Stem Cell Maintenance, Tumor Initiation and Metastatic Potential.”

MMPs have previously been implicated in lung tumor proliferation, invasion, and metastasis. The Mayo team’s own prior work suggested that Mmp10 is needed for transformed growth and invasion of human NSCLC cells in vitro, and mediates tumor initiation through the control of tumor-initiating bronchio-alveolar stem cell expansion.

Building on these findings the investigators have now looked more closely at the role of Mmp10 in the maintenance and tumorigenic potential of fully transformed mouse lung CSCs, a cell population characterized by stem-like properties including increased anchorage-independent growth in vitro, and enhanced tumor initiation, growth, and metastatic spread as orthotopic tumors in syngeneic mice.

The CSCs in these oncosphere cultures were found to express high levels of mRNAs for numerous genes associated with stem cell phenotype, and also high levels of Mmp10, but not other MMPs previously linked with lung cancer. The cultures in addition secreted much higher levels of Mmp10 protein into the medium in comparison with parental or redifferentiated cultures. As expected, oncosphere cultures demonstrated a loss of stem cell markers and Mmp10 expression when allowed to redifferentiate in adherent culture.

Notably, using an Mmp10-targeting RNAi to knock down Mmp10 mRNA expression in the oncosphere cultures led to an inhibition of transformed growth, loss of stem cell markers, and inhibition of clonal expansion, without impacting on cell viability. These effects could be restored by the addition of exogenous Mmp10.

Initial tests in vivo showed that while transplanting cells from oncosphere cultures into the lungs of syngeneic mice routinely led to the development of large tumors, cells from Mmp10-knockdown cultures generated fewer and small tumors, and also fewer metastases.

Importantly, the role of Mmp10 in tumorigenesis related to the gene’s expression by CSCs specifically, and not by other cells in the tumor environment. When the researchers injected unmodified oncospheres into Mmp10 knockout mice, tumor growth, size, and metastasis were equivalent to those resulting from the injection of unmodified oncospheres into wild-type syngeneic mice. This indicates that “Mmp10 expressed by oncospheres, but not from Mmp10 produced by other tumor-associated cells, is critical for tumor formation,” they write.

In a final set of analyses, the team analyzed publicly available gene-expression datasets of human tumors and found a strong positive correlation between Mmp10 expression and metastatic potential not only in human NSCLC, but also in colorectal cancer, melanoma, breast cancer, renal cell carcinoma, and prostate cancer.

The observation that Mmp10 appears to play a dual role in cancer, both in terms of maintaining the cancer stem cell population and facilitating metastasis, was an unexpected finding, the investigators note. Most other MMPs are expressed in the tumor microenvironment and cells and tissues surrounding the tumor, where they act to modify the tumor environment and facilitate cancer cell spread, Dr. Field explains. Conversely, “Mmp10 acts to keep these cancer stem cells healthy and self-renewing, which also helps explain why these cells escape conventional chemotherapy that might destroy the rest of the tumor.”

The team is now trying to define the mechanism by which Mmp10 stimulates the growth of cancer stem cells, and identify the design of inhibitors that block its activity. “Given the dual role in cancer stem cells and metastasis, targeting Mmp10 may be especially effective in treating these tumors,” he concludes.

Source: http://www.genengnews.com/gen-news-highlights/researchers-find-gene-key-to-maintaining-lung-cancer-stem-cells-promoting-tumor-initiation-and/81246678/

Biotie Regains Asia-Pacific Rights for VAP-1 Antibody Program from Seikagaku

Biotie Therapies and Seikagaku have agreed to terminate their license agreement for Biotie’s VAP-1 antibody program, BTT-1023. The decision also nixes Seikagaky’s option for Biotie’s VAP-1 SSAO small molecule inhibitors.

Biotie had granted Seikagaku exclusive development and commercialization rights in Japan, Taiwan, Singapore, New Zealand, and Australia in April 2003, and the arrangement was built around Seikagaku’s expertise in locomotive diseases. “Based on recently generated exciting data in animal models, we have reprofiled the VAP-1 antibody program to primarily target fibrotic diseases, and this therapeutic focus is no longer aligned with Seikagaku’s business strategy,” explains Timo Veromaa, CEO of Biotie.

“Regaining the Asia-Pacific rights to BTT-1023 gives us the opportunity to build a fully global development strategy in the fibrosis disease area, which has a high level of unmet medical need,” Veromaa notes.

BTT-1023 is a fully human mAb that specifically binds to VAP-1. Biotie previously demonstrated encouraging efficacy and safety for BTT-1023 in early clinical studies in RA and psoriasis patients as well as in a range of preclinical models of inflammatory diseases including COPD plus certain neurological conditions.

More recently, Biotie generated data indicating that VAP-1 also has an important role in fibrotic diseases. This data, generated in part in collaboration with National Institute for Health Research Liver Biomedical Research Unit at the University of Birmingham, reveals significant potential for BTT-1023 in certain niche liver inflammatory fibrotic diseases, the company points out.

The VAP-1 antibody program is Phase II ready, according to Biotie. The company is currently optimizing the scale-up of the manufacturing process for BTT-1023 and expects to start proof-of-concept clinical studies in selected indications in the second half of 2012.

Source: http://www.genengnews.com/gen-news-highlights/biotie-regains-asia-pacific-rights-for-vap-1-antibody-program-from-seikagaku/81246672/

MiRagen Pockets $20M to Further miRNA-Based Drugs

MiRagen Therapeutics completed a $20 million Series B financing. The company will use the money to advance development of its miRNA-based therapeutics pipeline. The financing is being led by Remeditex with participation from miRagen’s existing investor syndicate, which includes Amgen Ventures, Atlas Venture, Boulder Ventures, and Broadview Ventures.

“In a short period of time, miRagen has delivered significant advances that help to translate new biology into next-generation therapeutic candidates,” notes Bruce Booth, D.Phil., miRagen’s chairman of the board and partner at Atlas Venture. “The team has generated these compelling results in a capital-efficient manner, and we look forward to moving the company to the logical next level with the Series B investment.”

MiRagen’s pipeline is at the preclinical stage. The antimiR program is the most advanced and comprises three candidates. These molecules are aimed at chronic heart failure, post myocardial infarction (MI) remodeling, and polycythemia vera. MiRagen also has one candidate at the lead optimization stage, which is being evaluated in cardiac fibrosis. Additionally, there are four drug compounds in target validation studies against peripheral arterial disease, cardiometabolic disease, vascular disease, and amyotrophic lateral sclerosis.

Additionally, miRagen is coupling its expertise with outside partners. This January it signed an agreement with Silence Therapeutics to evaluate the potential combination of the latter’s DBTC delivery system with its own miRNA-based therapeutics. The chronic heart failure and post-MI remodeling candidates are partnered with Servier. In October 2011, Servier paid $45 million up front for these two drugs as well as a yet to be identified cardiovascular target. If all milestones are reached in all three programs, the deal will total $1 billion to miRagen.

MiRagen is also working with Santaris Pharma in cardiovascular and muscle diseases, using Santaris’ locked nucleic acid drug platform. Additionally, miRagen entered into a collaboration with RXi to evaluate the potential utility of RXi’s rxRNA technology against specific miRNA targets of interest to miRagen in the areas of cardiac and neuromuscular disease.

The company has exclusive rights to the technology and intellectual property related to the in vivo use of discoveries made by the University of Frankfurt and licensed by t2cure regarding miR-92, a regulator of neoangiogenesis as part of ischemic disease. Furthermore the firm has license arrangements for discoveries made at the University of Texas, University of North Carolina, and University of Colorado.

Source: http://www.genengnews.com/gen-news-highlights/miragen-pockets-20m-to-further-mirna-based-drugs/81246671/

Novo Nordisk, Kennedy Institute Partner on Rheumatoid Arthritis Drug and Biomarker R&D

Novo Nordisk is partnering with Oxford University’s Kennedy Institute of Rheumatology in the U.K. for the discovery and development of new biomarkers and drug targets for rheumatoid arthritis and other inflammatory autoimmune diseases. Under terms of the agreement, Novo Nordisk will fund 10 researchers at the Kennedy Institute to work within the partnership.

The Institute has in the past made key discoveries in the field of rheumatoid arthritis pathobiology, and its head, professor Sir Marc Feldman, M.D., was one of the co-discoverers of anti-TNF as a therapeutic approach to the disease. The translational research center will work in partnership with Novo Nordisk to apply its expertise to the discovery of new treatments.

“As a translational research center, we are keen to do clinical research on truly innovative ideas that have the potential to improve how patients with autoimmune inflammatory disease are treated today,” professor Feldman remarks. “We will work closely together with Novo Nordisk to apply the most advanced translational research approaches available for discovering new mechanisms and validating drug targets and candidates in autoimmune inflammatory disease in a variety of human disease tissue types and at different stages of disease, to ensure comprehensive characterization of each compound’s clinical potential.”

Source: http://www.genengnews.com/gen-news-highlights/novo-nordisk-kennedy-institute-partner-on-rheumatoid-arthritis-drug-and-biomarker-r-d/81246669/

Scientists Identify Potential Target for Treating Cocaine Addiction

Scientists report new insights into the mechanism by which repeated exposure to cocaine induces addiction. The studies in mice demonstrate that cocaine downregulates the active form of Rac1, a small GTPase known to control actin remodelling, and that this leads to enhanced actin turnover, and increases the density of immature dendritic spines on nucleus accumbens (NAc) neurons in the brain’s key reward center.

The researchers, led by a team at Mount Sinai School of Medicine’s Fishberg Department of Neuroscience and Friedman Brain Institute, showed in mice that overexpression of a dominant negative mutant of Rac1 or local knockout of the native gene was enough to increase the density of immature dendritic spines on the NAc neurons, without cocaine administration. Encouragingly, transiently increasing levels of Rac1 blocked the addiction-causing effects of repeated cocaine use and the accompanying neural changes.

Reporting their findings in Nature Neuroscience, Eric J. Nestler and colleagues suggest their results could help in the design of new treatments for cocaine addiction. Their paper is titled “Rac1 is essential in cocaine-induced structural plasticity of nucleus accumbens neurons.”

“The research gives us new information on how cocaine affects the brain’s reward center and how it could potentially be repaired,” Dr. Nestler says. “This is the first case in the brain in vivo where it’s been possible to control the activity of a protein, inside nerve cells in real time. Our findings reveal new pathways and targets.”

Source: http://www.genengnews.com/gen-news-highlights/scientists-identify-potential-target-for-treating-cocaine-addiction/81246662/

Oligomerix Raises $2M for Tau Protease Inhibitor Alzheimer Disease Program

Oligomerix raised $2 million in a Series A round of financing to progress its tau protease inhibitor program for treating Alzheimer disease. The financing round comprises both the issue of new convertible preferred shares and debt conversion.

Oligomerix is focused on the development of small molecule drugs and immunotherapeutics that target neurotoxic tau oligomers for the treatment of Alzheimer disease and related neurodegenerative disorders. The tau protease inhibitor program aims to neutralize tau outside of neurons, which the firm says is a more feasible drug discovery approach than targeting intraneuronal tau oligomer formation. The firm has developed a compound screening assay to identify disease-modifying small drugs and antibody-based therapeutics targeting tau oligomers and their proteolytic activity.

“Our research has shown that inhibiting tau oligomer protease may be an effective intervention for not only improving cognitive function, but also interrupting disease progression in Alzheimer disease,” comments James Moe, Ph.D., president and CEO. “Oligomerix’ primary goal is to identify, optimize, and select three to five lead NCEs to enable in vivo studies in a tauopathy mouse model to isolate candidates for IND-enabling studies…Based on our research, the well-characterized reproducible pattern of the initiation and spread of pathological aggregates of tau protein during the progression of Alzheimer disease provides a direct intervention point for tau protein’s mechanism of action, and a druggable target.”

Four of the firm’s product development programs have received grant funding from the NIH, the National Institute of Aging, and the Alzheimer’s Drug Discovery Foundation. In November 2011 Oligomerix was awarded a $1.6 million Phase II Small Business Innovation Research from the NIH to progress its tau-targeting small molecule and antibody programs, both for drug development and biomarker applications.

Source: http://www.genengnews.com/gen-news-highlights/oligomerix-raises-2m-for-tau-protease-inhibitor-alzheimer-disease-program/81246660/

Iris Pharma, RxGen Partner on Integrated Ophthalmology Research Services

French firm Iris Pharma and RxGen have established an alliance through which they aim to provide fully integrated bench-to-bedside ophthalmology research services to the pharma and biotech industries worldwide. Iris specializes in preclinical and clinical ophthalmic contract research, while U.S.-based RxGen is a preclinical CRO focused on the development and application of translational research models.

Through their new collaboration Iris will be able to offer access to RxGen’s nonhuman primate ophthalmic research models and related preclinical in vivo services, through a flexible model that will allow clients to access both firms’ combined preclinical and clinical expertise and capabilities. Iris says the ability to offer integrated packages of services and a comprehensive suite of preclinical and clinical drug development services will represent a significant benefit for clients.

“The combination of RxGen’s in vivo ophthalmic capabilities in nonhuman primates and Iris Pharma’s world-leading position in ophthalmology positions us to provide superior innovative and adaptive services that will speed time to market for our customers,” comments Christopher Stanley, chief business officer of RxGen.

Source: http://www.genengnews.com/gen-news-highlights/iris-pharma-rxgen-partner-on-integrated-ophthalmology-research-services/81246655/

Device sought for early screening

By Carly Harrington
Posted April 15, 2012 at 4 a.m.
Every year when it’s time for her routine physical exam, Nancy Munro’s family practice physician will place electrodes to her chest and run an electrocardiogram to check the health of her heart.

The simple, low-cost EKG test, which records the electrical activity of a person’s heart, takes a matter of seconds and gives her doctor something to look at to determine if there are any problems.

Munro, a retired ORNL researcher, believes a similar method could be used to help primary care doctors detect signs of early Alzheimer’s disease and mild cognitive impairment.

“They only acquire data for 30 seconds, and the doctor can look at it and very quickly decide whether it looks OK or not. That’s the kind of thing we’re aiming for,” she said. “Our goal is to develop a device that can be used in the primary care setting, whether it’s a doctor’s office or a community hospital, that will quickly give a reliable discrimination between normal aging and possibly clinically significant memory problems.”

Munro has been collaborating with fellow scientists at ORNL and the universities of Kentucky and Tennessee to develop an early screening tool using data from an electroencephalogram, or EEG, which measures electrical activity in the brain.

The method was inspired by the work of fellow ORNL researcher Lee Hively, who had developed a way to analyze data, including EEG data, forewarning of epileptic seizures.

“As I got to know more about his research, we discussed the possibility of looking at other brain disorders, and one of the things we discussed was Alzheimer’s,” said Munro, whose mother-in-law had been severely affected by the disease.

The group conducted a pilot project using data collected by the University of Kentucky from three groups of patients — patients with no dementia symptoms, patients diagnosed with mild cognitive impairment and patients diagnosed with early Alzheimer’s.

An analysis done via a collaboration between ORNL and the University of Tennessee showed positive results in distinguishing between the three.

Meanwhile, a working memory test, which could be used in a memory disorders clinic, was added to the study.

When looking at the EEG signals from the different parts of the brain, the mild cognitive impairment group processed the data more like the Alzheimer’s folks did, Munro said.

“They’re showing more activity in a different part of the brain than what the normal pattern is.

“It’s parallel to the Alzheimer’s group, so it shows that there is a difference in how the brain is functioning between the normal and the mild cognitive impairment group,” she added.

The group is now in the process of seeking additional funding to expand its initial study.

Munro said their approach would give a better basis for knowing whether someone should be referred to a specialist or not.

It also could be used in the drug discovery process by providing a low cost way of assessing whether the compounds they’re trying to develop are helpful.

“What we’re trying to do is not aimed at untangling the disease mechanism at all,” she said.

“It’s trying to get at very early changes, just as early as possible so we can identify people and get treatment.”

Get Copyright Permissions © 2012, Knoxville News Sentinel Co.
Want to use this article? Click here for options!

© 2012 Knoxville News Sentinel. All rights reserved.

Source: http://www.knoxnews.com/staff/carly-harrington/